-
公开(公告)号：US20190194623A1
公开(公告)日：2019-06-27
申请号：US16250366
申请日：2019-01-17
Applicant: BioNTech AG , TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg Univers
Inventor： Ugur Sahin , Marco Poleganov , Tim Beissert
IPC: C12N5/074
CPC classification number: C12N5/0696 , C12N2510/00
Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
-
公开(公告)号：US10253373B2
公开(公告)日：2019-04-09
申请号：US15591896
申请日：2017-05-10
Applicant: BioNTech AG , Johannes Gutenberg-Universität Mainz
Inventor： Ugur Sahin , Özlem Türeci , Michael Koslowski
IPC: C12Q1/68 , C12Q1/6886 , C07K14/47 , C07K16/30
Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
-
73.发明申请公开(公告)号：US20190062762A1
公开(公告)日：2019-02-28
申请号：US16143520
申请日：2018-09-27
Applicant: BioNTech AG
Inventor： Ugur Sahin , Silke Holtkamp , Ozlem Tureci , Sebastian Kreiter
Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
-
公开(公告)号：US20180177885A1
公开(公告)日：2018-06-28
申请号：US15895402
申请日：2018-02-13
Applicant: BioNTech AG
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
CPC classification number: A61K47/64 , A61K48/00 , C07K14/4748 , C07K14/70539 , C07K2319/02 , C07K2319/03
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
-
75.发明申请MODIFICATION OF RNA, PRODUCING AN INCREASED TRANSCRIPT STABILITY AND TRANSLATION EFFICIENCY 审中-公开RNA的修饰，产生增加的转录稳定性和翻译效率公开(公告)号：US20170009244A1
公开(公告)日：2017-01-12
申请号：US15217555
申请日：2016-07-22
Applicant: BioNTech AG
Inventor： Ugur Sahin , Silke Holtkamp , Ozlem Tureci , Sebastian Kreiter
Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
Abstract translation: 本发明的目的是提供具有增加的稳定性和翻译效率的RNA以及获得这种RNA的手段。 通过在基因治疗方法中使用所述RNA可以获得更高等级的表达。
-
Patent Agency Ranking
公开(公告)号：US20160250323A1
公开(公告)日：2016-09-01
申请号：US15023052
申请日：2013-09-26
Applicant: BIONTECH AG , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄT SMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Inventor： Ugur Sahin , Heinrich Haas , Sebastian Kreiter , Yves Hüsemann , Mustafa Diken , Kerstin Reuter , Hossam Hefesha
CPC classification number: A61K39/39 , A61K9/1271 , A61K9/1277 , A61K9/5073 , A61K31/675 , A61K39/0011 , A61K2039/55505 , A61K2039/55511 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/572 , C12N15/88 , C12N2810/10
Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.
Abstract translation: 本发明涉及RNA修饰的颗粒，例如RNA修饰的脂质颗粒，优选涉及RNA修饰的脂质体。 此外，本发明涉及包含RNA修饰的颗粒如RNA修饰的脂质颗粒，优选RNA修饰的脂质体的药物组合物。 所述药物组合物可用于诱导免疫应答。 它也可用于预防和/或治疗涉及抗原的疾病。 此外，本发明涉及用于制备RNA装饰颗粒的方法，例如RNA修饰的脂质颗粒，优选RNA修饰的脂质体。
-
77.发明申请公开(公告)号：US20160215351A1
公开(公告)日：2016-07-28
申请号：US15003530
申请日：2016-01-21
Applicant: BioNTech AG
Inventor： Ugur Sahin , Ozlem Tureci , Michael Koslowski
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C07K14/4748 , C07K16/30 , C12Q2600/118 , C12Q2600/158
Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
Abstract translation: 本技术涉及与癌症疾病相关的遗传产物。 本技术还涉及遗传产物表达或异常表达，特别是癌症疾病的疾病的治疗和诊断。
-
公开(公告)号：US20160058853A1
公开(公告)日：2016-03-03
申请号：US14647577
申请日：2013-11-26
Applicant: BIONTECH AG , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTEN-BERG-UNIVER
Inventor： Ugur Sahin , Claudia Paret , Kirsten Vormbrock , Christian Bender , Jan Diekmann
IPC: A61K39/00
CPC classification number: A61K39/0011 , A61K2039/53 , A61K2039/55561 , A61K2039/572 , A61K2039/605 , A61K2039/627
Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
Abstract translation: 本发明涉及靶向肿瘤抗原，特别是共享的肿瘤抗原的个体表达模式的患者特异性肿瘤治疗和个体肿瘤突变。 一方面，本发明涉及一种用于预防或治疗患者癌症的方法，包括以下步骤：（i）诱导针对患者中一种或多种肿瘤抗原的第一免疫应答，和（ii）诱导第二免疫 对患者中一种或多种肿瘤抗原的反应，其中第二免疫应答对存在于患者的癌细胞中的癌症特异性体细胞突变是特异性的。
-
公开(公告)号：US20160002738A1
公开(公告)日：2016-01-07
申请号：US14796509
申请日：2015-07-10
Applicant: BioNTech AG
Inventor： Ugur Sahin , Özlem Türeci , Michael Koslowski
IPC: C12Q1/68
CPC classification number: C07K16/30 , A61K38/00 , A61K39/00 , A61K39/39558 , A61K48/00 , C07K14/4748 , C07K16/3015 , C07K16/3023 , C07K16/3053 , C07K16/3069 , C07K2317/34 , C07K2317/76 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/574
Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
-
80.发明授权Identification of tumor-associated cell surface antigens for diagnosis and therapy 有权鉴定肿瘤相关细胞表面抗原进行诊断和治疗公开(公告)号：US09139880B2
公开(公告)日：2015-09-22
申请号：US13863780
申请日：2013-04-16
Applicant: BioNTech AG
Inventor： Özlem Türeci , Ugur Sahin , Gerd Helftenbein , Volker Schlüter
IPC: C12Q1/68 , C07K14/47 , C07K14/705 , C07K16/30 , G01N33/574 , A61K39/00
CPC classification number: G01N33/57492 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K16/30 , C07K2317/34 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N2800/56
Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.
Abstract translation: 本发明提供具有肿瘤抑制活性的药剂，并且其对表达或异常表达肿瘤相关抗原的细胞是选择性的。 所述肿瘤相关抗原具有选自以下的核苷酸序列：（a）选自本文所述的特定序列的核苷酸序列或其6-50个连续核苷酸残基部分; （b）在严格条件下与具有（a）的核苷酸序列的核酸杂交的核酸的核苷酸序列; （c）相对于（a）或（b）的核苷酸序列退化的核苷酸序列; 和（d）与（a），（b）或（c）的核苷酸序列互补的核苷酸序列。 还提供了包含这些试剂的药物组合物和试剂盒，以及治疗，诊断或监测以肿瘤相关抗原的表达或异常表达为特征的疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.091 seconds)
